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Abstract
Background: Post-surgical adhesion bands (PSABs) are a 
common complication after abdominal or pelvic surgeries 
for different reasons like cancer treatment. Despite improve-
ments in surgical techniques and the administration of drugs 
or the use of physical barriers, there has only been limited 
improvement in the frequency of postoperative adhesions. 
Complications of PSAB are pain, infertility, intestinal obstruc-
tion, and increased mortality. The most important molecular 
mechanisms for the development of PSAB are inflammatory 
response, oxidative stress, and overexpression of pro-fibrot-
ic molecules such as transforming growth factor β. However, 
questions remain about the pathogenesis of this problem, 
for example, the causes for individual differences or why cer-
tain tissue sites are more prone to post-surgical adhesions. 
Summary: Addressing the pathological causes of PSAB, the 
potential role of local angiotensin II/angiotensin II type 1 re-
ceptors (AngII/AT1R), may help to prevent this problem. Key 
Message: The objective of this article was to explore the role 
of the AngII/AT1R axis potential to induce PSAB and the ther-
apeutic potential of angiotensin receptor blockers in the pre-
vention and treatment of PSAB. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Post-surgical adhesion band (PSAB) formation is a 
clinical and surgical challenge because it can lead to pain, 
bowel and fallopian tube obstruction, infertility, and ad-
ditional therapeutic costs [1, 2]. PSAB is a common post-
operative complication, although the risk of formation of 
these adhesion bands appears to be increased in patients 
undergoing abdominal surgery or gynecological pelvic 
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operations [3, 4]. Trauma during surgery, the hypoxia, 
and infection are the most important etiological factors 
that are likely to be involved in PSAB [5]. Despite advanc-
es in medicine and in surgical techniques, and producing 
biological barriers such as Seprafilm, PSAB remains a 
medical challenge and extensive research is necessary.
The renin-angiotensin system (RAS) comprises several 
peptides that are released into the bloodstream to main-
tain blood pressure hemostasis and act on target organs. 
AngII is an octapeptide, with a principal effect on regulat-
ing vasoconstriction, inflammation, and fibrosis by inter-
action with the AngII type 1 receptor (AT1R) [6, 7]. The 
AT1R is a G-protein-coupled protein that interacts with 
AngII and mediates the intracellular signaling pathways. 
It has recently been reported that local RAS components 
such as AT1R and AngII are expressed in several organs 
include the gastrointestinal tract, kidney, lung, liver, and 
other organs. AngII signaling through local AT1R is as-
sociated with extracellular matrix (ECM) deposition fol-
lowing enhanced synthesis of proteins in ECM and leads 
to an increased risk of fibrosis in the liver [6], lung [8] and 
scar formation in the skin [9]. AngII/AT1R interactions 
can promote some molecular mechanisms related to fi-
brosis such as the transforming growth factor β (TGF-β)/
Smad axis [10], nuclear factor kappa B (NF-κB) activation, 
and increased inflammation and oxidative stress (OS) [11, 
12]. This review aims to explain some of the molecular 
mechanisms of the AngII/AT1R axis to induce post-sur-
gical adhesion through the promotion of signaling path-
ways and pro-fibrotic molecule expression.
Post-Surgical Adhesion Pathogenesis
Acute inflammation and the recruitment of immune 
cells and platelet to the injured area after surgery occur in 
the normal wound healing process; phagocytes cells re-
move tissue debris and dead cells and release cytokines 
and chemokines that amplify inflammatory reactions. 
The proliferation of fibroblasts and myofibroblasts and 
their migration to the injured area enable them to pro-
mote wound closure [13, 14]. In fibrotic conditions, for 
example, during post-operative fibrotic band formation, 
excess immune cell recruitment causes chronic inflam-
mation. A high concentration of inflammatory cytokines 
and growth factors like TGF-β and platelet-derived 
growth factor occur in chronic inflammation [15]. Ex-
perimental animal studies and analysis of adhesion tis-
sues in humans have shown that an imbalance in the ex-
pression of cytokines and growth factors is an important 
factor in the pathogenesis of adhesion formation [16, 17]. 
Excessive proliferation and migration of fibroblasts and 
myofibroblasts in the injured area promote the expres-
sion of TGF-β, which is the most important profibrotic 
mediator in tissue fibrogenesis [18]. The over-expressed 
TGF-β enhances the expression of collagens and tissue 
inhibitor of metalloproteinase in ECM and decreases the 
expression of matrix metalloproteinase (MMPs), and this 
increases ECM stiffness [19]. Tissue remodeling is an im-
portant stage of normal wound healing. The MMPs are 
involved in maintaining a balance between degradation 
and accumulation of ECM and help tissue remodeling. 
The down-regulation of MMPs by TGF-β impairs ECM 
degradation persuade ECM deposition [20]. Also, TGF-β 
can stimulate the expression of plasminogen activator in-
hibitor-1 (PAI-1) [21]. PAI reduces the fibrinolytic activ-
ity by reduction of tissue plasminogen activation (tPA) to 
help the accumulation of the fibrin gel matrix [22, 23]. OS 
is one of the other pathological causes of post-surgical 
adhesion formation. Hypoxia during the surgery contrib-
utes to the migration of immune cells moving toward the 
hypoxic area, so it leads to the production of reactive ox-
ygen species (ROS) that accelerate inflammation and 
stimulate adhesion formation [24]. The pathological 
mechanism related to PSAB is summarized in Figure 1.
Roles of AngII/AT1R in TGF-β Signaling
Recent studies have demonstrated that RAS compo-
nents such as AT1R and AngII are expressed in different 
organs, including the gastrointestinal tract [25], liver 
[26], peritoneum [27], pancreas [28], and other organs. 
Injuries and trauma to tissues during surgery stimulates 
an increased expression of AT1R and promotes several 
molecular signaling pathways related to fibrosis. Paizis et 
al. showed that after liver injury, a significant expression 
of local AT1Rs was seen in injured tissue and fibrotic state 
in the liver [29]. Suekane et al. analyzed colonic stricture 
tissues from patients with Crohn’s disease and found that 
fibroblasts and fibro-muscular in fibrotic tissues strongly 
expressed the AT1R [30]. Also in pathological fibrotic cu-
taneous conditions, there is an increased expression of 
AngII/ATIRs and TGF-β [31]. The TGF-β/SMAD signal-
ing pathways are 1 of the most important pathways asso-
ciated with organ fibrosis that are induced through sev-
eral mechanisms up-regulated by local AT1Rs. AngII by 
interaction with AT1R induces the MAPK pathway [32]. 
The MAPK pathway ERK1/2 or P38 up-regulates down-
stream profibrotic genes that include TGF-β. In addition 
protein kinases, ERK, or P38 stimulated with AngII/
AT1R can phosphorylate and active Smad complex di-
rectly to promote fibrotic molecules expression [33]. 
TGF-β is a pro-fibrotic molecule that plays an essential 
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role in the pathology of post-operative adhesion and fi-
brosis in different organs [34, 35]. TGF-β binds to its re-
ceptors and subsequently stimulates the intracellular 
Smad signaling cascade, enhancing the expression of 
genes related to fibrotic proteins such as collagen I and 
α-SMA. Moreover, TGF-β strongly promotes the differ-
entiation of myofibroblasts and the synthesis of ECM 
proteins [36]. Besides, TGF-β1 inhibits MMPs and the 
activation of tissue inhibitor metalloproteinase and there-
by stimulates ECM deposition and stiffness [37]. Telmis-
artan, an AT1R antagonist, reduces post-surgical abdom-
inal adhesion by inhibiting the expression of TGF-β and 
collagen [38]. Dinarvand et al. have shown that intra-
peritoneal administration of Losartan, another AT1R an-
tagonist, reduced postoperative abdominal adhesion 
through significant changes of serum concentration and 
mRNA expression of TGF-β and PAI-1 as fibrotic mole-
cules [39]. With respect to the role of AngII/AT1R in the 
induction of TGF-β/Smad signaling pathways to promote 
fibrosis, AT1R antagonists may have preventive and ther-
apeutic potential to reduce the risk of PSAB in a patient 
who is due to have surgery. The potential effects of AngII/
AT1R activity in TGF-β/Smad signaling are briefed in 
Figure 2.
Association between AngII/AT1R, Inflammation,  
and OS
There is a positive feedback between AngII/AT1R and 
inflammation. Upregulation of AT1R may contribute to 
an increased expression of molecules related to inflam-
Fig. 1. Pathological reasons for post-surgical adhesion formation after abdominal surgeries or organ transplanta-
tion. TGF-β, transforming growth factor β; PAI, plasminogen activator inhibitor; tPA, tissue plasminogen acti-





mation and OS [40]; hence, the AT1R promotes inflam-
mation and OS by different molecular mechanisms. In-
flammation increases the release of ROS, leading to OS 
that appears to be an essential process in PSAB and fibro-
sis. Monocyte chemoattractant protein-1 is an important 
member of chemokine proteins involved in the process-
es related to inflammation, and this is up-regulated by 
AngII through AT1R signaling [41]. Moreover, AT1Rs 
directly induce NF-kB and its signaling, which leads to 
producing different inflammatory and adhesive cyto-
kines such as IL6, IL1β, TNF-α, TGF-β, ICAM-1, and E-
selectin [42]. The AngII/AT1Rs axis can reduce peroxi-
some proliferator-activated receptors (PPARγ) which 
have an anti-inflammatory role [42]. Injuries of the ab-
dominal or pelvic peritoneum during surgery lead to ac-
tivation of AT1Rs on the surfaces of mesothelial and fi-
broblasts which induce inflammatory and adhesive mol-
ecules to stimulate PSAB in the peritoneal or pelvic 
cavity [43]. We found that the intra-peritoneal adminis-
tration of telmisartan after abdominal surgery in a rat 
model significantly reduced the expression of the inflam-
matory cytokines TNF-α and IL6 through AT1Rs inhibi-
tion [38]. After tissue injuries, the accumulation of im-
mune cells and fibroblasts in the injured area can stimu-
late the NF-kB signaling pathway to increase 
inflammatory cytokines such as TNF-α and promote the 
formation of ROS [44]. Through the release of ROS, the 
AngII/AT1R pathway may reduce nitric oxide synthesis 
and activate NF-kB indirectly. OS is a potential regulator 
in the pathogenesis of PSAB. OS is associated with the 
release of increased levels of ROS that include superox-
ide, hydrogen peroxide, and hydroxyl radical, with im-
paired activity of the antioxidant system. NOXs (NADH 
oxidase) are a group of enzymes to produce ROS local-
ized in different tissues that catalyze the conversion of 
oxygen to superoxide molecule (O2−) to increase OS [45–
48]. Interaction of AT1R with activation of AngII causes 
molecular mechanisms to lead to the stimulating of NOX 
isoforms to produce ROS and OS. One study showed that 
AngII with AT1R stimulation causes NOX isoform acti-
vation in hepatic stellate cells, and induce OS, leading to 
liver fibrosis [49]. In unilateral ureteral obstruction and 
Fig. 2. Effects of AngII on the TGF-β/SMAD signaling pathway, 
inflammation, OS and fibrosis pathway. Binding of ANGII to 
AT1R, irritate MAPK complex to activate SMAD complex to enter 
the nucleus and express fibrotic genes. NF-kB activated by AngII/
AT1R interaction increase the expression of molecules related to 
inflammation. AngII up-regulates the expression of NOX that help 
to increase of OS. These pathological conditions are parallel with 
adhesion formation post-surgical pathogenesis. NF-kB, nuclear 
factor kappa B; TGF-β, transforming growth factor β; OS, oxida-
tive stress; NOX, NADH oxidase; AngII/AT1R angiotensin II/an-
giotensin II type 1 receptor; ROS, reactive oxygen species.
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fibrosis, AT1Rs were increased and may stimulate the 
expression of NOX isoforms to induce OS and inflam-
mation related to fibrosis; Kim et al. [50] showed that 
fimasartan treatment leads to the down-regulation of 
NOX and OS level by AT1Rs inhibition. Other studies 
have indicated that blocking AngII binding to AT1 re-
ceptors can reduce superoxide generation by reducing 
molecular mechanisms related to inflammation and 
NOX expression, thus reducing OS. Potential effects of 
AT1R on signaling pathways related to inflammation 
and OS are summarized in Figure 2.
AngII/AT1R and Fibrotic Molecules Expression
Fibrinolytic activity after trauma in tissues such as the 
peritoneal layer after peritoneal or pelvic surgeries is an 
essential activity for tissue remodeling and the wound 
healing process [51]. Two molecules associated with fibri-
nolysis activity are tPA and PAI, and the balance between 
these molecules is necessary for a normal wound healing 
process, but in PSAB, an imbalance between tPA and PAI 
toward PAI expression inhibits fibrinolytic activity and 
induces fibrinogenesis, thereby increasing the risk of 
PSAB [52]. PAI is a protease inhibitor that inhibits the 
tPA activity, reduces the fibrinolytic action of cells, and 
increases the risk of fibrin gel matrix accumulation and 
fibrosis [53, 54]. The up-regulation of AngII/AT1Rs in-
creases the expression of PAI by different molecular 
mechanisms. PAI expression is regulated by the TGF-β/
Smad signaling pathways [55]. AngII/AT1Rs leads to ac-
tivation of p38 MAPK and c-Jun N-terminal kinases, and 
contributes to the TGF-β/Smad signaling pathway that is 
a regulator for PAI expression [32, 55]. Moreover, AngII 
can stimulate PAI expression through TNF-α; Takeshita 
et al. [56] have shown that local up-regulated AngII/
AT1Rs stimulate PAI-1 production in vitro in human he-
patic hepatocytes cell line and found that angiotensin 
AT1 receptor antagonists inhibit TNF-α mediated ex-
pression of PAI-1. Rosella et al. [57] have demonstrated 
that Losartan can reduce PAI expression and PAI level in 
rat nonalcoholic fatty liver disease model.
One of the other fibrotic molecules involved in the 
pathogenesis of PSAB is α-smooth muscle actin (α-SMA) 
(actin alpha 2). α-SMA is a marker for fibrogenic activity 
produced by fibroblast and myofibroblasts, key cells in 
organ fibrogenesis, overexpressed in PSAB [58]. Some 
studies have been focused on the role of AngII in the reg-
ulation of α-SMA expression. In vitro experiments in car-
diomyocytes showed that AngII up-regulate the expres-
sion α-SMA that promotes cardiac hypertrophy [59]. 
Kurikawa et al. [60] have reported that AT1R expression 
is up-regulated in the fibrotic area of the liver and hepat-
ic stellate cells increase the mRNA expression of collagen 
I and α-SMA, and they found that olmesartan, an antago-
nist of AT1R, decreases the expression of fibrotic mole-
cules collagen I and α-SMA, and improves liver fibrosis. 
Because of the roles of AngII/AT1R signaling to stimulate 
profibrotic molecules expression, AT1R blockers may be 
considered to be novel therapies in the prevention of fi-
brogenesis. The roles of AngII/AT1R in cancer progres-
sion are summarized in Table 1.
Table 1. Key points of AngII/AT1R effects in the pathogenesis of PSAB.
AngII/AT1R axis effects
TGF-β/Smad signaling Stimulation of MAPK complex signaling pathways by AngII/AT1R leads to both TGF-β gene 
expression directly and active the phosphorylation of Smad2/3 to upregulate genes such as TIMP and 
PAI related to fibrotic conditions like PSAB
Inflammation and oxidative 
stress
AT1Rs directly induce NF-κB signaling pathways which lead to producing different inflammatory 
and adhesive cytokines such as IL6, IL1β, TNF-α, TGF-β, and ICAM-1 that are important in PASB 
pathogenesis. Increase inflammatory cytokines such as TNF-α promote the formation of ROS. Also, 
AngII/AT1R interaction causes molecular mechanisms to lead to the stimulating of NOX isoforms to 
produce ROS and OS
Fibrotic molecules expression The upregulation of TGF-β/Smad signaling pathways by AngII/AT1Rs is a regulator for PAI 
expression that is a fibrotic molecule and important in PSAB pathogenesis. Also, α-SMA important 
molecules in fibrosis are promoted by AngII/AT1R axis
α-SMA, α-smooth muscle actin; PSAB, post-surgical adhesion band; PAI, plasminogen activator inhibitor; NF-kB, nuclear factor 
kappa B; TGF-β, transforming growth factor β; ROS, reactive oxygen species; OS, oxidative stress; NOX, NADH oxidase; AngII/AT1R, 





Therapeutic Potential of Angiotensin Receptor 
Blockers in PSAB
Angiotensin receptor blockers (ARBs) are a group of 
drugs that usually are administrated for the treatment of 
hypertension in the clinic. Besides the anti-hypertensive 
effects of ARBs, recent studies have demonstrated that 
these drugs have the potential to reduce inflammation, 
OS, and fibrosis in different organs. These findings pro-
vided new insights that this family can have the potential 
to prevent or reduce post-surgical adhesion. Arjmand et 
al. [38] have shown that telmisartan could significantly 
decrease post-surgical fibrotic bands in comparison with 
the control group in the rat model. They found that 
telmisartan was able to reduce inflammatory mediators 
such as IL6, TNF-α, and TGF-β; also, the OS index was 
decreased and anti-oxidant capacity was increased. More-
over, they showed that the expression of fibrotic genes 
collagen 1 and 3 was significantly decreased in the group 
of treatment with telmisartan [38]. Dinarvand et al. [39] 
have demonstrated that Losartan decreases post-surgical 
adhesion in the mouse model. Intraperitoneal adminis-
tration of losartan significantly decreased fibrotic bands 
after the adhesion induction model. They founded that 
Losartan was able to reduce both TGF-β and PAI-1 con-
centration in serum and mRNA expression in peritoneal 
tissues. More results observed that serum concentrations 
of tPA and its mRNA level in peritoneal tissues were in-
creased in animals that received losartan [39]. In other 
studies, candesartan can reduce adhesion formation us-
ing an experimental model of peritoneal adhesions; can-
desartan can decrease the severity of adhesion formation 
using an experimental model of peritoneal adhesions in 
the rat. Tokinaga et al. [61] found that intraperitoneal ad-
ministration of candesartan reduces PAI-1 mRNA ex-
pression in injured tissues and was able to reduce the ad-
hesion score. These findings suggested that using these 
drugs in patients for surgeries may have the potential to 
prevent post-surgical adhesion.
Conclusion
We provided a novel insight into the molecular mech-
anisms by which activated local AngII/AT1Rs after sur-
gery may increase the risk of PSAB and fibrogenesis. This 
review article was focused on molecular mechanism of 
AngII/AT1R in increasing the expression of TGF-β, and 
other fibrotic molecules followed it, development of in-
flammation, and OS that these molecular events facilitate 
the formation of fibrotic bands post-operative. Based on 
the pathological role of local AngII/AT1R signaling after 
special abdominal or pelvic surgeries, the administration 
of ARBs may be considered as a new and efficient thera-
py to prevent postsurgical adhesions. More (pre-)clinical 
researches should be performed to receive better infor-
mation on the clinical significance of ARBs against PSAB 
formation during urological, abdominal, or pelvic sur-
geries.
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